Tag Archives: Difei Yang

Mizuho Securities Maintains Their Hold Rating on Abeona Therapeutics (ABEO)

In a report released today, Difei Yang from Mizuho Securities maintained a Hold rating on Abeona Therapeutics (ABEO – Research Report), with a price target of $4.00. The company’s shares closed last Monday at $2.94. According to TipRanks.com, Yang has

Zogenix (ZGNX) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Difei Yang maintained a Buy rating on Zogenix (ZGNX – Research Report) today and set a price target of $65.00. The company’s shares closed last Monday at $46.83. According to TipRanks.com, Yang ‘s ranking currently consits of

Mizuho Securities Maintains Their Buy Rating on Viewray (VRAY)

Mizuho Securities analyst Difei Yang maintained a Buy rating on Viewray (VRAY – Research Report) today and set a price target of $9.00. The company’s shares closed last Monday at $4.18. According to TipRanks.com, Yang has currently no stars on

Viewray (VRAY) Gets a Buy Rating from Mizuho Securities

Mizuho Securities analyst Difei Yang reiterated a Buy rating on Viewray (VRAY – Research Report) today and set a price target of $9.00. The company’s shares closed last Monday at $3.40. According to TipRanks.com, Yang is ranked 0 out of

Revance Therapeutics (RVNC) Received its Third Buy in a Row

After Needham and Stifel Nicolaus gave Revance Therapeutics (NASDAQ: RVNC) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Difei Yang maintained a Buy rating on Revance Therapeutics today and set a price

Mizuho Securities Sticks to Its Buy Rating for Akebia Therapeutics (AKBA)

In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report), with a price target of $16.00. The company’s shares closed last Monday at $3.07, close to its 52-week low